New antibody ABBV-383 takes on Hard-to-Treat blood cancer

NCT ID NCT07420959

Not yet recruiting Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study tests a new drug called ABBV-383 in 38 people with Waldenström macroglobulinemia that has come back or not responded to treatment. The drug is a monoclonal antibody designed to block cancer growth. The trial has two parts: first finding a safe dose, then checking how well it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABBV-383 (a monoclonal antibody)
What this could lead to: If it works, this could offer a new treatment option for people with Waldenström macroglobulinemia that has returned or stopped responding to other therapies.
What could go wrong: This is an early-phase trial with only 38 participants, so results may not apply to everyone. The antibody may cause side effects or not work well enough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT WALDENSTROM MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT WALDENSTROM MACROGLOBULINEMIA REFRACTORY WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.